General Information
Product name
QIR-MR
Subspeciality
Cardiac
Modality
MR
Disease targeted
Myocardial infarction, Myocarditis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Amyloidosis, Fabry disease, Sarcoïdosis, Aortic aneurysm, Iron overload. coronary artery disease, Aortic, mitral and tricuspid valve diseases, stress-induced cardiomyopathy (Tako-Tsubo syndrom)
Main task
Not specified
Technical Specifications
Population
All adult patients qualified for an MR exam
Patient population age
Not specified
Input
MR sequences, 2D, 2D+t, cine images, delayed enhancement images (phase-contrast images, first pass dynamic images), aorta images, mapping images (T1,T2,T2*), multi frame
Input format
DICOM
Output
Table of quantified values, analysis report, segmentation overlay, assessment of pathology presence
Output format
CSV, DICOM SR, HL7, HTML, PDF
Integration
Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment
Locally on dedicated hardware
Trigger for analysis
Etc., Image upload, On demand, Triggered by a user through e.g. a button click
Processing time
10 seconds - 10 minutes ( depends on the type of study)
Regulatory Information
CE Certification
Pathway:
MDD
Class:
Class IIa
Verified by Health AI Register
FDA Certification
Pathway:
510(k) cleared
Class:
Class II
Verified by Health AI Register
Other certifications
Not specified
Market Presence
On market since
06-2018
AI Platforms
Not specified
Resellers
Not specified
Countries present
18 countries
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
One-time license fee, Pay-per-use, Subscription
Based on
Number of analyses, Number of installations, Number of users
Evidence & Research
No research papers or evidence available for this product.
Source: vendor | First published: Jun 4, 2024 | Last updated: Jul 10, 2025